GlassScriptPhysician profile
Harsh Mehta
NPI 1518489566
$2,277.37
in general payments reported to CMS, 2019-2025
10 companies · $771 in 2025
The $771 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.23 · 2023: $152 · 2024: $1,340 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,263.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $766.22 | 2024-2025 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $335.49 | 2024-2025 | Impella |
| Abbott Laboratories | $333.17 | 2024-2025 | Xience Skypoint, Cardiomems |
| Boston Scientific Corporation | $328.71 | 2024-2025 | Watchman Flx, General - Vascular Access |
| Penumbra, INC. | $139.34 | 2024 | Indigo System |
| Cardiva Medical, INC. | $126.24 | 2024 | Cardiva Vascade 6/7f Vcs |
| Medtronic, INC. | $82.03 | 2024 | Symplicity G3 |
| Kiniksa Pharmaceuticals, LTD. | $79.94 | 2023 | Arcalyst |
| Chiesi USA, INC. | $72.00 | 2023 | Kengreal |
| Csl Behring | $14.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsh Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.